Search results
There's a new COVID-19 variant called FLiRT: Here's what you need to know about it
USA Today· 1 day agoA new set of COVID-19 variants, nicknamed FLiRT, has been detected in wastewater surveillance,...
H.C. Wainwright drops Enanta Pharmaceuticals shares target on RSV program progress By Investing.com
Investing.com· 4 hours agoThis move comes after Enanta Pharmaceuticals provided an update on its ongoing clinical trials for...
S2 Episode 5: Epidemiology of RSV in Adults
Medscape· 6 days agoFor more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Forest W....
Pregnant Woman Gets Married at Florida Hospital While in Labor: 'It All Happened So Fast'
People via Yahoo News· 22 hours agoDue to being hospitalized with RSV, Brianna Lucca-Cerezo had to be induced early, dashing her...
Here's Why GSK (GSK) is a Strong Value Stock
Zacks via Yahoo Finance· 2 hours agoGSK sits at a Zacks Rank #3 (Hold), holds a Value...
Moderna to seek parity for RSV shot (NASDAQ:MRNA)
Seeking Alpha· 6 days agoModerna (MRNA) stock gains as the company highlights its upcoming RSV shot, expecting the U.S. regulators to endorse it on par with rival products. Read more here.
What to know about the new 'FLiRT' COVID variants that are spreading: Your guide to the latest virus...
Yahoo Life· 2 days agoHere’s your go-to guide with everything you need to know about COVID-19, including the latest...
Earnings call: Enanta Pharmaceuticals Q2 fiscal results and pipeline updates By Investing.com
Investing.com· 23 hours ago:ENTA), a biopharmaceutical company focused on developing oral therapeutics, reported its financial...
Moderna Focused on Cutting Costs, RSV Vaccine
Bloomberg· 6 days agoModerna Chief Executive Officer Stéphane Bancel talks about how the biotech giant is cutting costs and developing new vaccines. The drugmaker expects to...
Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant ...
Benzinga· 6 days agoBeyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations New real-world evidence shows Beyfortus (nirsevimab) substantially ...